Understanding heterogeneity in the context of recurrent aGCTs is important, herein consistent preservation of the heterozygous mutation in primary and recurrent lesions supports a view that c. 402C>G FOXL2 is indeed a driver gene for aGCT and this tumor retains dependence on the functions of the mutant protein. This evidence concerns the gene FOXL2 and neoplasm.